Matthew Wein files SEC Form 4 disclosures for Metagenomi, Inc.. They have made 7 open-market trades across 1 company since 2025, most recently 2026-09-08.
CIK 0002009713
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| MGX | 126,133 | $101K |
Shares reported on the most recent Form 4, priced at the 2026-09-10 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| MGX | SELL | 2026-09-08 | 2026-09-10 | $1.16 | $415 | -4.6% | -14.3% | — |
| MGX | SELL | 2026-06-05 | 2026-06-10 | $1.30 | $725 | +0.8% | +2.8% | -6.1% |
| MGX | SELL | 2026-03-05 | 2026-03-09 | $1.60 | $771 | -8.2% | -12.6% | -18.6% |
| MGX | SELL | 2025-12-05 | 2025-12-08 | $1.77 | $352 | -8.3% | -0.6% | -11.6% |
| MGX | SELL | 2025-09-05 | 2025-12-01 | $1.81 | $360 | +6.1% | -1.2% | -6.7% |
| MGX | SELL | 2025-06-06 | 2025-06-09 | $1.75 | $348 | -15.2% | +36.3% | +8.8% |
| MGX | SELL | 2025-03-05 | 2025-03-07 | $1.87 | $2K | -16.6% | -30.2% | -19.0% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.